Skeletal muscles are essential for both energy metabolism and physical movement. A reduction in skeletal muscle mass can lead to functional and metabolic complications. Ongoing research aims to avert these conditions by enhancing muscle mass and regenerative potential. While Ginsenoside Rg5 is known for its diverse pharmacological properties, research specifically addressing its impact on muscle development and differentiation remains limited. To explore the influence of Rg5 on myogenesis, C2C12 myoblasts underwent differentiation in the presence of Rg5. Subsequently, qRT-PCR, immunostaining, and immunoblotting were utilized to evaluate promyogenic signaling (p38MAPK) and myogenic markers. Immunoprecipitation analyses demonstrated that Rg5 enhanced the p38MAPK-mediated interaction between E2A and MyoD. To assess the protective effects of Rg5 against muscle wasting, C2C12 myotubes were exposed to dexamethasone to stimulate muscle atrophy. Molecular techniques, including qRT-PCR, immunostaining, and immunoblotting, were then applied to analyze myogenic markers, atrophy-associated genes (MuRF1 and Atrogin-1), and the Akt/mTOR protein synthesis pathway. The application of Rg5 advanced the differentiation of C2C12 myoblasts by driving MyoD/E2A heterodimerization and p38MAPK phosphorylation. Additionally, Rg5 prompted hypertrophy in C2C12 myotubes through the phosphorylation of the Akt/mTOR pathway. The resulting phosphorylation of Akt triggered FoxO3a phosphorylation, thereby downregulating the expression of both MuRF1 and Atrogin-1. This research elucidates the mechanisms by which Rg5 facilitates myogenesis and muscle hypertrophy while counteracting dexamethasone-induced atrophy. To our knowledge, this is the initial report demonstrating that Rg5 enhances muscle regeneration, highlighting its potential as a therapeutic strategy for managing muscle wasting and weakness, such as cancer cachexia.
